



Published in final edited form as:

*Cancer Epidemiol Biomarkers Prev.* 2012 November ; 21(11): 2033–2042. doi:  
10.1158/1055-9965.EPI-12-0799.

## Iron in Relation to Gastric Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study

Michael B. Cook<sup>1</sup>, Farin Kamangar<sup>1,2</sup>, Stephanie J. Weinstein<sup>1</sup>, Demetrius Albanes<sup>1</sup>, Jarmo Virtamo<sup>3</sup>, Philip R. Taylor<sup>1</sup>, Christian C. Abnet<sup>1</sup>, Richard J. Wood<sup>4,5</sup>, Gayle Petty<sup>5</sup>, Amanda J. Cross<sup>1</sup>, and Sanford M. Dawsey<sup>1</sup>

<sup>1</sup>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA <sup>2</sup>Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, MD, USA <sup>3</sup>Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland <sup>4</sup>School of Public Health and Health Sciences, University of Massachusetts, MA, USA <sup>5</sup>Nutrition Evaluation Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA

### Abstract

**Background**—Iron is an essential micronutrient that can have carcinogenic effects when at high or low concentrations. Previous studies of iron in relation to gastric cancer have not assessed subtype-specific relationships. We used the prospective ATBC Cancer Prevention Study to assess whether iron metrics were associated with gastric cardia cancer (GCC) and gastric noncardia cancer (GNCC).

**Methods**—We selected 341 incident gastric cancer cases (86 cardia, 172 noncardia, and 83 non-specified), accrued during 22 years of follow-up, and 341 individually matched controls. We measured prediagnostic serum iron, ferritin, unsaturated iron binding capacity (UIBC), and C-reactive protein. Total iron binding capacity (TIBC) and transferrin saturation were estimated from these metrics. Dietary iron exposures were estimated from a food frequency questionnaire. Multivariable logistic regression was used for analysis.

**Results**—Serum iron metrics were not associated with GCC, except for a potential ‘n’-shaped relationship with TIBC (global  $p=0.038$ ). GNCC was inversely associated with serum ferritin (global  $p=0.024$ ), serum iron (global  $p=0.060$ ) and, possibly, transferrin saturation. TIBC appeared to share a ‘u’ shaped relationship with GNCC (global  $p=0.033$ ). Dietary iron exposures were not associated with either subsite. Adjustment for *Helicobacter pylori* and gastric atrophy had little effect on observed associations.

**Conclusions**—We found little evidence for the involvement of iron exposure in the pathogenesis of GCC. GNCC was associated with an iron profile similar to that of iron deficiency.

### Keywords (MeSH)

*Helicobacter pylori*; Iron; Nested Case-Control Studies; Prospective Studies; Stomach Neoplasms

---

Corresponding author: Michael Blaise Cook, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd, EPS/Suite 550/Room 5014, Bethesda, MD 20852-7234, phone: 301-496-1613, fax: 301-402-0916, michael.cook@nih.gov.

There are no financial disclosures from any of the authors.

**Impact:** Our findings indicate that inverse associations between iron metrics and gastric cancer are driven by associations with GNCC. Further elucidation of potential mechanisms is warranted.

## Introduction

Iron is an essential micronutrient involved in oxygen transport and cellular oxidative metabolism. The concentration of iron in humans accumulates with age in most populations, a result of dietary iron exceeding loss and the lack of a biological mechanism to excrete excess levels (1). This is important because iron can induce oxidative DNA damage via free radical generation (2, 3) and high iron levels have been positively associated with cancer risk (4, 5). In addition, heme iron can catalyze endogenous formation of N-nitroso compounds, which are potent carcinogens. Increasing the complexity of the potential carcinogenic roles of iron is evidence that deficient levels may also increase risk of malignancy.

Gastric cancer is one such malignancy that has been associated with low levels of serum iron (6–8). Although all previous studies have assessed total gastric cancer, the pathology of this malignancy is now recognized to be subsite-specific. *Helicobacter pylori* (*H. pylori*) infection leading to gastric atrophy and then cancer is the de facto multistep pathway of gastric noncardia cancer (GNCC) (9). Gastric cardia cancer (GCC), meanwhile, presents a distinct risk profile more aligned with that of esophageal adenocarcinoma—such as gastroesophageal reflux, increased body mass index, and tobacco smoking—which may result from heterogeneous etiologies within this single subsite (10). If iron is associated with gastric malignancies, it is possible that *H. pylori* infection could mediate this association, given that it is positively associated with GNCC (11–14), potentially inversely associated with GCC (12–15), and has been associated with reduced iron levels in the human body (16, 17).

To investigate the relationships between iron and gastric cancer subsites, including the potential effects of *H. pylori*, we conducted a nested case-control study in the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study, a prospective cohort of over 29,000 men in Finland.

## Methodology

The rationale, design, and results of the ATBC Cancer Prevention Study have been described in detail (18). In brief, the ATBC Cancer Prevention Study was a randomized, double-blind, placebo-controlled, 2 × 2 factorial primary prevention trial that tested whether daily supplementation with alpha-tocopherol (50 mg) and/or beta-carotene (20 mg) could reduce the incidence of lung and other cancers (19). A total of 29,133 Caucasian, male smokers, aged 50–69 years and living in southwestern Finland, were recruited from 1985 to 1988. All subjects provided written informed consent. During the two clinical visits prior to randomization, study participants completed a life-style factor questionnaire and a 276-item food frequency questionnaire (FFQ). In addition, fasting blood samples were collected from participants, the sera of which were stored at –70°C. The intervention concluded on April 30, 1993, but the participants continue to be followed as a cohort using the Finnish Cancer Registry which provides almost 100% case coverage (20). The ATBC Cancer Prevention Study was approved by the institutional review boards of the National Cancer Institute, Bethesda, Maryland, and the National Public Health Institute, Helsinki, Finland.

## Study subjects

Cases were subjects of the ATBC Study cohort who were diagnosed with gastric cancer through April 30, 2006, a follow-up of up to 21 years. Gastric cancer was defined according to the International Classification of Diseases, 9th Revision (21) code 151, and were subclassified as GCC if they involved the esophagogastric junction and as GNCC if they did

not. Eligible cases were required to have at least 500  $\mu\text{l}$  of serum available for analysis. The total number of eligible cases, based on these criteria, was 341. Eighty-six of these gastric cancer cases were coded as GCC and 172 as GNCC; the remaining 83 were coded as gastric cancer not otherwise specified. Controls were matched to cases in a 1:1 ratio using the variables age at randomization ( $\pm 1$  year) and date of blood draw ( $\pm 30$  days). Each of these variables were highly correlated between cases and matched controls ( $r=0.999$ ). Controls were required to be alive and cancer-free up until the date of cancer diagnosis of their matched case.

### Exposure assessment

The primary exposures of this study were: serologic biomarkers of iron and its bound state, which included quantitation of ferritin, iron, and unsaturated binding capacity (UIBC) and calculation of total binding capacity (TIBC) and transferrin saturation; and dietary iron, total iron, and a proxy of heme iron intake measured using a FFQ.

All serologic iron assays were performed by Drs. Richard Wood and Gayle Petty at Tufts University. Serum ferritin was quantitated using an immunoradiometric assay (Count-A-Count Ferritin IRMA: Diagnostic Products Los Angeles). Serum iron and UIBC were measured using a standard ferrozine-based iron colorimetric assay (Olympus AU 400e auto analyzer). Total-iron-binding capacity (TIBC) ( $\mu\text{g}/\text{dl}$ ) was calculated as the sum of UIBC ( $\mu\text{g}/\text{dl}$ ) and serum iron ( $\mu\text{g}/\text{dl}$ ). Transferrin saturation (%) was calculated as  $[\text{serum iron } (\mu\text{g}/\text{dl})/\text{TIBC } (\mu\text{g}/\text{dl})] \times 100$ . Serum ferritin is an indicator of iron stored in the body and is a correlate of heme iron intake (22). Serum iron represents the amount of circulating iron bound to transferrin. UIBC is the amount of transferrin not currently bound to iron; the residual capacity. TIBC represents the blood's capacity to bind iron with transferrin. Transferrin saturation is the percentage of transferrin currently bound to iron. Ferritin is an acute phase reactant, thus we also measured high-sensitivity C-reactive protein (CRP), a marker of systemic inflammation, to enable adjustment (23). CRP was quantitated using a latex particle enhanced immunoturbidimetric assay kit (K-ASSAY CRP Ultra, Equal Diagnostics, Extom, PA).

For quality control purposes we included 36 serum samples aliquoted from a single large pool of serum from ATBC Cancer Prevention Study participants. These 36 samples were distributed among the 9 assay plates (4 samples per plate). On the basis of these samples, the coefficients of variation (CVs) were 3.8% for ferritin, 25.5% for serum iron, 7.7% for UIBC, and 5.7% for CRP. However, three of the serum iron measurements were clearly outliers at values of 109 (plate 2), 147 (plate 2) and 175 (plate 3) compared with the mean and standard deviation (mean: 75.9, sd:1.9) of the remaining 33 samples. When these three samples were excluded, the CV for serum iron was 2.5%. There were no differences in overall, control or case distributions of iron amongst the nine analytic plates. Furthermore, internal low and high iron concentration standards were stable across all analytic plates and produced CV's of 1.0% and 2.0%, respectively.

The FFQ aimed to assess the usual frequency of consumption of foods over the past 12 months. Study subjects were also asked to approximate portion sizes of foods, using a provided guide with 3 to 5 different portion sizes for each of the different food types. The FFQ was linked to a food-composition database of the National Public Health Institute in Finland, to estimate intake of: *dietary iron* (dietary iron); *total iron* (dietary iron and supplemental iron); *heme iron proxy* (dietary pork, beef, liver and other organ meats); as well as the intake of potential enhancers (e.g. meat and vitamin C) and inhibitors (e.g. alcohol, fiber, and calcium) of iron absorption. Dietary iron, total iron, and heme iron proxy exposure variables were adjusted for energy intake (kcal) using the nutrient density model (e.g.,  $[\text{dietary iron}/\text{kcal}] \times 1000$ ) so that the variable was expressed as units (e.g. grams) per

1000 kcal. Dietary information was available only for 312 cases, 320 controls, and 292 matched-sets, and for a few of these subjects some individual dietary responses were also missing.

For purposes of statistical adjustment and effect modification analyses, we also assessed serum for biomarkers of *H. pylori* infection and gastric atrophy. *H. pylori* seropositivity was assessed using immunoglobulin G antibodies against *H. pylori* whole-cell by an enzyme linked immunosorbent assay (Biohit ELISA kit, Finland). Each plate included two quality control samples provided by the kit (a negative control and a positive control) and three blinded quality control samples from a single serum pool from the ATBC Cancer Prevention study. Cases, controls, and QC samples were all measured in duplicate. Seropositivity was defined as  $\geq 30$  enzyme-immunosorbent units. Concordance between QC samples was 100%. Serum pepsinogen I (PGI) is a serologic marker of gastric atrophy. PGI was measured using a radioimmunoassay, as previously described (24), and subjects with  $\text{PGI} < 25\mu\text{g/l}$  were defined as having gastric atrophy (24, 25). PGI measurements were available for only 218 cases, 310 controls, and 206 matched sets.

### Statistical analysis

Primary exposure variables were assessed for correlations. These primary exposures were analyzed as ordinal variables (quartiles) with categorical cut-points based on control distributions. Conditional logistic regression models and unconditional logistic regression models, adjusted for matching factors, were conducted to estimate odds ratios (OR) and 95 percent confidence intervals (95% CI); results from both sets of models were similar, thus we present the unconditional models herein as they allowed inclusion of a greater number of subjects. Minimally adjusted models included the covariates age at randomization, date of blood draw, and trial intervention (alpha-tocopherol and beta-carotene; each dichotomous). Additional covariates for the fully adjusted models were chosen by whether they altered an exposure's estimate by more than 10%. Because of the interrelatedness amongst serum iron metrics, and amongst dietary iron metrics, chosen additional covariates were repeated for other models within the same exposure category (serum/dietary). Unless otherwise specified, covariates were modeled as continuous metrics. Fully adjusted models for serum exposures included the covariates age at randomization, date of blood draw, trial intervention (alpha-tocopherol, beta-carotene; each dichotomous), energy intake (kcal/day), CRP (mg/l), fiber intake (g/day), education (categorical), and total vitamin C intake (diet and supplements; mg/day). Fully adjusted models for dietary exposures included the covariates age at randomization, date of blood draw, trial intervention, fiber intake, education, total calcium intake (diet and supplements; mg/day), vegetable intake (g/day), energy intake (kcal/day), cigarettes per day smoked, and years of cigarette smoking. Further models, for both serum and dietary exposures, were adjusted for the additional variables of *H. pylori* (dichotomous) and gastric atrophy (dichotomous). Note that when adjustment was made for dietary exposures some individuals could not be included due to missing data. Due to the fact that many of the categorical results presented non-linear exposure-disease relationships, we calculated global p values using the likelihood ratio test to compare nested models to main models with the addition of the quartiled categorical exposure of interest. All logistic regression models were conducted for the outcomes gastric cancer and subsite-specific groups (GCC and GNCC).

To test for differences in serum markers of iron by *H. pylori* seropositivity and presence of gastric atrophy, we used the t-test for transformed normally distributed exposures. In addition, we estimated the global p value (as previously described) with adjustment for case-type and case-control status. We also conducted analyses to determine whether exposures and/or exposure-outcome relationships were different when stratified by *H. pylori* seropositivity, gastric atrophy, and CRP level. To investigate the possibility of reverse

causation we conducted sensitivity analyses whereby cancers diagnosed *within* 3 years post-blood draw were excluded. Lastly, to investigate potential short-term effects mediated by these exposures we conducted sensitivity analyses whereby cancers diagnosed *after* 15 and 12.5 years post-blood draw were excluded. Two-sided p-values <0.05 were considered to be statistically significant. All analyses were conducted using STATA version 11.2 (Stata-Corp LP, College Station, TX).

## Results

Table 1 shows the descriptors of all participants for each variable pertinent to this analysis of iron and gastric cancer. As can be seen, GCC and GNCC cases smoked slightly more cigarettes per day than controls. In addition, GNCC cases had fewer years of schooling, were more likely to be *H. pylori* seropositive and positive for gastric atrophy, consumed slightly less fiber, and had lower levels of serum ferritin and serum iron, compared with control subjects.

Table 2 shows the correlations between age at blood draw, serum iron markers, and dietary iron exposures. Moderate to high correlations were observed for the following pairs of variables: serum iron and transferrin saturation ( $r=0.87$ ,  $p<0.001$ ); transferrin saturation and UIBC ( $r=-0.67$ ,  $p<0.001$ ); and, TIBC and UIBC ( $r=0.82$ ,  $p<0.001$ ).

Table 3 shows the results of the fully adjusted logistic regression models; minimally adjusted models showed similar patterns of relationships between exposures and outcomes (data not shown). Serum ferritin shared a 'u'-shaped relationship with gastric cancer, with the third quartile and the global p value being statistically significant ( $OR_{3rd\ quartile}=0.52$ , 95% CI: 0.33–0.82,  $p=0.005$ ; global  $p=0.037$ ). All other serum measures and dietary iron were not associated with all gastric cancer cases combined.

Site-specific analyses, meanwhile, provided fairly distinct results. There was limited evidence for associations of iron metrics with GCC—only TIBC was associated with this outcome with an apparent 'n'-shaped relationship (global  $p=0.038$ ). For GNCC, there was stronger evidence for associations with iron metrics. Both serum ferritin and serum iron shared inverse, or possibly 'u'-shaped, relationships with this malignancy (serum ferritin  $OR_{3rd\ quartile}=0.36$ , 95% CI: 0.18–0.71,  $p=0.003$ ; global  $p=0.024$ ; serum iron  $OR_{3rd\ quartile}=0.39$ , 95% CI: 0.19–0.78,  $p=0.008$ ; global  $p=0.060$ ). In addition, TIBC appeared to share a 'u'-shaped relationship with GNCC ( $OR_{3rd\ quartile}=0.51$ , 95% CI: 0.26–1.00,  $p=0.051$ ; global  $p=0.033$ ). Lastly, the point estimates for transferrin saturation were suggestive of an inverse, or decreased risk with a threshold-effect, relationship with GNCC, albeit none of these p values were less than 0.05.

Adjustment for *H. pylori* and then gastric atrophy did not materially affect a majority of the estimates (data not shown)—the only exception was that the relationship between ferritin and GNCC was attenuated ( $OR_{2nd\ quartile}=0.92$ , 95% CI: 0.39–2.16,  $p=0.85$ ;  $OR_{3rd\ quartile}=0.46$ , 95% CI: 0.18–1.17,  $p=0.11$ ;  $OR_{4th\ quartile}=1.02$ , 95% CI: 0.45–2.31,  $p=0.96$ ; global  $p=0.31$ ). There was little evidence for direct associations between iron metrics and *H. pylori* seropositivity or gastric atrophy (low pepsinogen I)—only serum ferritin appeared to share a relationship with these variables, and this relationship was stronger between ferritin and gastric atrophy (Table 4). Restricting analyses to individuals with low CRP levels ( $< 10$  mg/l; 308 [90.3% of] cases, 314 [92.1% of] controls), individuals seropositive for *H. pylori*, or individuals without gastric atrophy did not materially alter the results (data not shown). There were too few individuals who were *H. pylori* negative or gastric atrophy positive to permit analysis of such groups. Sensitivity analyses with exclusion of cancers *within* 3 years post-blood draw (Supplementary Table), or exclusion of

cancers diagnosed *after* 15 or 12.5 years post-blood draw (data not shown) did not materially affect the estimates attained.

## Discussion

In this analysis of serologic and dietary metrics of iron exposure in the prospective ATBC Cancer Prevention Study, we found limited evidence for association of iron metrics with GCC. For GNCC, we observed inverse relationships with the exposures serum ferritin, serum iron, and, possibly, transferrin saturation—an iron profile similar to that of iron deficiency.

There have been seven previously published papers from five studies which have assessed associations between serum iron metrics and gastric cancer (Table 5). Four of the papers represent three cohort studies: a mobile health clinic study based in Finland (4), the first National Health and Nutrition Examination Survey (NHANES I) (26, 27), and a cohort of the Kaiser Permanente Multiphasic Health Check-up Evaluation Study (28). The remaining three previously published papers come from two nested case-control studies, one based in the Hiroshima and Nagasaki atomic bomb survivors cohort (8) and the other in the Honolulu Heart Program cohort of men with Japanese ancestry (7, 29). All of these studies used prediagnostic serum for analysis, and all studied all gastric cancers combined. Thus, there is no strict comparison for the subsite-specific results that we present herein. However, the predominant subsite of gastric cancer for the countries and periods covered by previous analyses has been GNCC (30–32), so the previous results may be somewhat comparable to the findings presented here for GNCC.

Serum ferritin was assessed in each of the two nested case-control studies. In an analysis of 208 gastric cancer cases and 350 matched controls from the Hiroshima and Nagasaki atomic bomb survivors cohort, Akiba *et al.* (8) found an inverse association between serum ferritin and gastric cancer (OR<sub>1st vs. 5th quintile</sub>=3.6,  $p<0.001$ ; case mean: 49 ng/ml, control mean: 69 ng/ml,  $p<0.05$ <sup>1,2</sup>).

In the second nested case-control study, Nomura *et al.* (7) compared the mean ferritin levels of 121 gastric cancer cases (198 ng/ml) with 121 matched controls (242 ng/ml) and found a borderline statistically significant result ( $p=0.05$ ). It is noteworthy that the absolute levels of serum ferritin appear to be much lower in Japan (8), relative to the higher levels detected in ATBC Cancer Prevention Study participants (case mean: 123 ng/ml, control mean: 144 ng/ml) and the even higher levels of Japanese Americans in the Honolulu Heart Program cohort (7). In general, however, the results from these studies support our finding of an inverse, or possibly 'u'-shaped, relationship between serum ferritin and gastric cancer, particularly GNCC.

Serum iron has been assessed in relation to gastric cancer by two of the aforementioned cohort studies and both found evidence for inverse associations (4, 26, 27). In the mobile health clinic study from Finland, 120 incident male gastric cancers and 76 incident female gastric cancers occurred during a mean follow-up of 14 years (4). The relationship in males was statistically significant (RR<sub>4th vs. 1st quartile</sub>=0.60,  $p$  for trend $<0.01$ ; case mean: 107.0  $\mu\text{g/dl}$ , control mean: 115.7  $\mu\text{g/dl}$ ,  $p<0.05$ ) while in females the estimate was similar albeit not statistically significant (RR<sub>4th vs. 1st quartile</sub>=0.59,  $p$  for trend=0.17; case mean: 95.7  $\mu\text{g/dl}$ , control mean: 99.9  $\mu\text{g/dl}$ ,  $p=0.05$ ), likely due to the smaller number of accrued cases. In an

<sup>1</sup>Note that all transformed means have been back-transformed to their original units.

<sup>2</sup>Akiba *et al.* 1991, used logarithm with base 10 for original transformation. Personal Correspondence Dr. Suminori Akiba, MD. Kagoshima University, Japan. akiba@m.kufm.kagoshima-u.ac.jp

eighteen-year follow-up of NHANES I, ten male incident gastric cancer cases had lower serum iron (93.9  $\mu\text{g}/\text{dl}$ ) compared with 2,908 males who did not develop cancer (106.2  $\mu\text{g}/\text{dl}$ ), although a comparison of these means was not statistically significant (27). Similar inverse relationships for serum iron and ferritin in relation to GNCC may be expected, given their correlation and the fact that former represents the amount of iron circulating in the body, while the latter is an indicator of iron stores.

Three cohort studies have analyzed transferrin saturation in relation to gastric cancer (4, 26–28). The Finnish study (4) found inverse associations in men ( $\text{RR}_{4\text{th vs. 1st quartile}}=0.55$ ,  $p$  for trend $<0.001$ ; case mean: 30.8%, control mean: 34.5%,  $p<0.01$ ) and women ( $\text{RR}_{4\text{th vs. 1st quartile}}=0.60$ ,  $p$  for trend $=0.10$ ; case mean: 27.2%, control mean: 28.9%,  $p>0.05$ ), although only in men was the relationship statistically significant. In both NHANES I (case mean: 26.0%, control mean: 30.7%,  $p=0.05$ ) (26, 27) and Kaiser Permanente ( $\text{RR}_{4\text{th vs. 1st quartile}}=0.64$ , 95%CI:0.21–1.9) cohorts, inverse but not statistically significant relationships were also reported in men, while the estimate for women in the Kaiser Permanente cohort showed a positive association which was borderline statistically significant ( $\text{RR}_{4\text{th vs. 1st quartile}}=3.5$ , 95%CI:0.98–12). These inverse associations reported in men from three cohorts lend support to the borderline statistically significant inverse association we report here between transferrin saturation and GNCC.

The last serum iron metric for which we found an association with GNCC was TIBC, and this appeared to be a ‘u’-shaped relationship. This is not supported by previous analyses: men, but not women, in the Finnish Mobile Health Clinic Study were found to have a statistically significant positive association between TIBC and gastric cancer ( $\text{RR}_{4\text{th vs. 1st quartile}}=1.29$ ,  $p$  for trend $<0.05$ ; case mean: 350.5  $\mu\text{g}/\text{dl}$ , control mean: 340.3  $\mu\text{g}/\text{dl}$ ,  $p<0.05$ ) and NHANES I found a similar difference in means (case mean: 361.7  $\mu\text{g}/\text{dl}$ , control mean: 350.9  $\mu\text{g}/\text{dl}$ ), although this difference was not statistically significant ( $p=0.05$ ). It is important to note that in an iron deficient population, TIBC would be expected to be increased.

With regards to dietary iron, we found no evidence to suggest associations with gastric cancer, GCC, or GNCC. This is in agreement with a recent analysis from the NIH-AARP cohort, a study which included 255 GCCs and 277 GNCCs, in which no evidence was found for an association with dietary heme iron (33). Our result is also supported by null results from an analysis of 132 GCCs and 203 GNCCs in EPIC, using dietary heme iron calibrated to 24 hour dietary recall to minimize between country differences (34). Of the three case-control studies to assess dietary iron in relation to gastric cancer, the largest study, which included 230 cases and 547 controls, found no evidence for association (35); of the two smaller case-control studies, the study from France study found evidence (36) and the US study found tentative evidence (37) for an inverse association between dietary iron and gastric cancer. In addition, there is scant evidence that red meat, a major food source of heme iron, is associated with gastric cancer (38) or subsites thereof (33).

Taken together, the results from previous studies and our own indicate an association between a serum iron profile consistent with iron deficiency and risk of GNCC. Whether this relationship is due to a causal mechanism or confounding remains unknown. Residual confounding via *H. pylori* is plausible given the ability of this bacterium to: induce hemorrhagic gastritis resulting in iron loss; induce gastric atrophy which reduces gastric acidity and ascorbic acid levels leading to poor absorption of iron; and sequester iron from the host for growth. Although we adjusted for *H. pylori* seropositivity, this biomarker is suboptimal in that it represents current or past exposure, time to seroreversion is variable (39), and it does not provide information as to the severity of infection. Arguing against confounding is the fact that associations changed very little: when adjusted for *H. pylori* and

gastric atrophy; when restricted to *H. pylori* seropositive or gastric atrophy negative individuals; or when cancers diagnosed in the first 3 years were excluded from analysis. It is equally plausible that the mechanism of association is causal. Iron deficiency may lead to increased levels of oxidative stress, decreased antioxidant defenses, reduced enzymatic activity leading to increased DNA damage, and increased genomic instability (6, 40). However, these mechanisms are still poorly understood and further research is required to further elucidate potential causal pathways of the observed associations presented herein.

Strengths of this study include that this is the largest study of the topic to date, it's the only study to evaluate both overall gastric cancer and the anatomic subsites thereof, and it used the most comprehensive set of iron assessment metrics. In addition it was nested in a prospective study with long-term follow-up which enabled use of pre-diagnostic serum and a detailed and validated FFQ (41). Lastly, we included sex-specific analyses only (male cohort) which avoided combination of the sexes which could result in type I or type II errors given the complexity of iron homeostasis in females. Limitations of this study include: three unexplained outlier aliquots of pooled serum used for the calculation of the CV for iron; possible inclusion of some lower esophageal adenocarcinomas among the GCCs; modest numbers of cases available in some of the subsite-specific groups; serum pepsinogen I being available for only a subset of participants; limited ability to interrogate the effects of *H. pylori* and gastric atrophy on the reported associations due to having few individuals negative for *H. pylori* or positive for gastric atrophy; lack of a female cohort as a comparison for the male results; and a population which includes only smokers, although we did adjust for duration and rate of exposure, where applicable.

In conclusion, this analysis of serologic and dietary metrics of iron exposure in the prospective ATBC Cancer Prevention Study finds little evidence for the involvement of iron exposure or homeostasis with GCC. GNCC was associated with an iron profile similar to that of iron deficiency, but reasons for this association remain unclear.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

### FUNDING

Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

## References

1. McCord JM. Iron, free radicals, and oxidative injury. *J Nutr.* 2004; 134:3171S–2S. [PubMed: 15514292]
2. Knutson MD, Walter PB, Ames BN, Viteri FE. Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. *J Nutr.* 2000; 130:621–8. [PubMed: 10702595]
3. Walter PB, Knutson MD, Paler-Martinez A, Lee S, Xu Y, Viteri FE, et al. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. *Proc Natl Acad Sci U S A.* 2002; 99:2264–9. [PubMed: 11854522]
4. Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliövaara M, Hakulinen T. Body iron stores and risk of cancer. *Int J Cancer.* 1994; 56:379–82. [PubMed: 8314326]
5. Stevens RG. Iron and the risk of cancer. *Med Oncol Tumor Pharmacother.* 1990; 7:177–81. [PubMed: 2146450]



6. Pra D, Rech Franke SI, Pegas Henriques JA, Fenech M. A possible link between iron deficiency and gastrointestinal carcinogenesis. *Nutr Cancer*. 2009; 61:415–26. [PubMed: 19838913]
7. Nomura A, Chyou PH, Stemmermann GN. Association of serum ferritin levels with the risk of stomach cancer. *Cancer Epidemiol Biomarkers Prev*. 1992; 1:547–50. [PubMed: 1302566]
8. Akiba S, Neriishi K, Blot WJ, Kabuto M, Stevens RG, Kato H, et al. Serum ferritin and stomach cancer risk among a Japanese population. *Cancer*. 1991; 67:1707–12. [PubMed: 2001562]
9. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res*. 1992; 52:6735–40. [PubMed: 1458460]
10. McColl KEL, Going JJ. Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia. *Gut*. 2010; 59:282–4. [PubMed: 20207629]
11. Siman JH, Engstrand L, Berglund G, Forsgren A, Floren CH. Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. *Scand J Gastroenterol*. 2007; 42:933–40. [PubMed: 17613922]
12. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. *J Natl Cancer Inst*. 2006; 98:1445–52. [PubMed: 17047193]
13. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. *Scand J Gastroenterol*. 1999; 34:353–60. [PubMed: 10365894]
14. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. *Gut*. 2007; 56:918–25. [PubMed: 17317788]
15. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst*. 1998; 90:150–5. [PubMed: 9450576]
16. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. *Helicobacter*. 2008; 13:323–40. [PubMed: 19250507]
17. Kearney DJ. Helicobacter pylori infection and iron deficiency anemia: accumulating evidence in support of a real association. *Indian J Gastroenterol*. 2005; 24:147–50. [PubMed: 16204900]
18. ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. *The ATBC Cancer Prevention Study Group Ann Epidemiol*. 1994; 4:1–10.
19. ATBC Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group N Engl J Med*. 1994; 330:1029–35.
20. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The finnish cancer registry as follow-up source of a large trial cohort: Accuracy and Delay. *Acta Oncol*. 2002; 41:381–8. [PubMed: 12234031]
21. World Health Organization. International classification of diseases : ninth revision: basic tabulation list with alphabetical index. Geneva: 1978.
22. Cade JE, Moreton JA, O'Hara B, Greenwood DC, Moor J, Burley VJ, et al. Diet and genetic factors associated with iron status in middle-aged women. *Am J Clin Nutr*. 2005; 82:813–20. [PubMed: 16210711]
23. Kalender B, Mutlu B, Ersoz M, Kalkan A, Yilmaz A. The effects of acute phase proteins on serum albumin, transferrin and haemoglobin in haemodialysis patients. *Int J Clin Pract*. 2002; 56:505–8. [PubMed: 12296612]
24. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group *Scand J Gastroenterol*. 2000; 35:950–6.
25. Laiyemo AO, Kamangar F, Marcus PM, Taylor PR, Virtamo J, Albanes D, et al. Serum pepsinogen level, atrophic gastritis and the risk of incident pancreatic cancer--a prospective cohort study. *Cancer Epidemiol*. 2009; 33:368–73. [PubMed: 19800305]

26. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. *N Engl J Med.* 1988; 319:1047–52. [PubMed: 3173433]
27. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. *Int J Cancer.* 1994; 56:364–9. [PubMed: 8314323]
28. Herrinton LJ, Friedman GD, Baer D, Selby JV. Transferrin saturation and risk of cancer. *Am J Epidemiol.* 1995; 142:692–8. [PubMed: 7572938]
29. Nomura AM, Stemmermann GN, Chyou PH. Gastric cancer among the Japanese in Hawaii. *Jpn J Cancer Res.* 1995; 86:916–23. [PubMed: 7493909]
30. Blaser MJ, Saito D. Trends in reported adenocarcinomas of the oesophagus and gastric cardia in Japan. *Eur J Gastroenterol Hepatol.* 2002; 14:107–13. [PubMed: 11981333]
31. Surveillance Epidemiology and End Results (SEER) Program. ([www.seer.cancer.gov](http://www.seer.cancer.gov)) SEER\*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2009 Sub (1973–2007) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969–2007 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission
32. Weiderpass E, Pukkala E. Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland. *BMC Gastroenterol.* 2006; 6:41. [PubMed: 17144908]
33. Cross AJ, Freedman ND, Ren J, Ward MH, Hollenbeck AR, Schatzkin A, et al. Meat Consumption and Risk of Esophageal and Gastric Cancer in a Large Prospective Study. *Am J Gastroenterol.* 2010
34. Jakszyn P, Agudo A, Lujan-Barroso L, Bueno-de-Mesquita HB, Jenab M, Navarro C, et al. Dietary intake of heme iron and risk of gastric cancer in the European prospective investigation into cancer and nutrition (EURGAST- EPIC) study. *Int J Cancer.* 2011
35. Pelucchi C, Tramacere I, Bertuccio P, Tavani A, Negri E, La Vecchia C. Dietary intake of selected micronutrients and gastric cancer risk: an Italian case-control study. *Ann Oncol.* 2009; 20:160–5. [PubMed: 18669867]
36. Cornee J, Pobel D, Riboli E, Guyader M, Hemon B. A case-control study of gastric cancer and nutritional factors in Marseille, France. *Eur J Epidemiol.* 1995; 11:55–65. [PubMed: 7489774]
37. Harrison LE, Zhang ZF, Karpel MS, Sun M, Kurtz RC. The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U. S. *Cancer.* 1997; 80:1021–8.
38. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. Washington, DC: AICR; 2007.
39. Kikuchi S, Ohgihara A, Hasegawa A, Miki K, Kaneko E, Mizukoshi H. Seroconversion and seroreversion of *Helicobacter pylori* antibodies over a 9-year period and related factors in Japanese adults. *Helicobacter.* 2004; 9:335–41. [PubMed: 15270748]
40. Pra D, Franke SI, Henriques JA, Fenech M. Iron and genome stability: An update. *Mutat Res.* 2012; 733:92–9. [PubMed: 22349350]
41. Pietinen P, Hartman AM, Haapa E, Rasanen L, Haapakoski J, Palmgren J, et al. Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. *Am J Epidemiol.* 1988; 128:655–66. [PubMed: 2458036]

**Table 1**  
 Descriptors of Participants Selected for Analysis of Iron Metrics in Relation to Gastric Cancer Nested in the ATBC Cancer Prevention Study

Variable	All Gastric Cancer		Gastric Cardia Cancer		Gastric Noncardia Cancer	
	Controls (n=341)	P value	Cases (n=86)	P value	Cases (n=172)	P value
Age (years)	58 (5)	0.935	59 (5)	0.302	59 (5)	0.533
Body mass index (kg/m <sup>2</sup> )	26 (4)	0.834	27 (4)	0.167	26 (4)	0.473
Cigarettes/day	19 (8)	<b>0.003</b>	22 (10)	<b>0.007</b>	20 (8)	<b>0.022</b>
Years Smoked	36 (8)	0.138	38 (7)	0.344	37 (10)	0.089
Education (% junior high or above)	18 (14-22)	<b>0.025</b>	20 (11-28)	0.735	10 (5-14)	<b>0.014</b>
<i>H. pylori</i> (%)	73 (68-78)	< <b>0.001</b>	74 (65-84)	0.782	91 (87-96)	<b>0.000</b>
Gastric atrophy (%)	9 (6-13)	< <b>0.001</b>	16 (6-26)	0.117	22 (14-31)	<b>0.001</b>
Ever daily use of aspirin (%)	16 (12-20)	0.514	18 (8-28)	0.684	13 (6-19)	0.466
<b>Dietary intake (daily)</b>						
Total energy (kcal)	2666 (695)	0.567	2566 (665)	0.253	2649 (725)	0.543
Fiber (g)	19 (10)	<b>0.006</b>	18 (9)	0.101	17 (8)	<b>0.011</b>
Alcohol (g)	16 (18)	0.666	15 (16)	0.822	18 (21)	0.560
Total vitamin C (mg)	144 (173)	0.360	118 (117)	0.670	136 (184)	0.340
Total calcium (mg)	1423 (575)	0.368	1370 (489)	0.586	1360 (530)	0.239
Supplemental iron use (%)	9 (6-12)	0.990	11 (4-17)	0.690	9 (5-14)	0.930
Dietary iron (mg)	18 (5)	0.128	17 (6)	0.208	18 (5)	0.101
Total iron (mg)	22 (27)	0.148	20 (9)	0.470	20 (18)	0.088
Heme iron proxy (g)	69 (31)	0.462	65 (32)	0.250	68 (28)	0.951
<b>Serum markers</b>						
Ferritin (ng/ml)	156 (95-241)	<b>0.008</b>	162 (89-267)	0.838	115 (68-211)	<b>0.002</b>
Iron (µg/dl)	117 (91-145)	0.443	119 (94-141)	0.843	108 (79-146)	<b>0.036</b>
Transferrin saturation (%)	36 (29-44)	0.647	38 (30-45)	0.460	35 (24-43)	0.096
TIBC (µg/dl)	329 (294-361)	0.779	319 (296-347)	0.261	321 (292-367)	0.701
UIBC (µg/dl)	202 (173-239)	0.842	200 (170-231)	0.206	206 (170-248)	0.621
CRP (mg/l)	2.1 (0.9-4.3)	0.910	2.4 (1.1-4.3)	0.405	2.1 (0.8-5.1)	0.651

The mean and standard deviation of each variable are provided, unless the variable is stated to be a percentage in which case the percentage and 95 percent confidence interval are provided, or unless the variable is a serum marker in which case the median and interquartile range (IQR) are provided.

Table 2

Pearson correlation coefficients between age, serum iron markers, and dietary iron among control subjects

	Pearson's correlation coefficients (r)									
	Age at blood draw (years)	Ferritin (ng/ml)	Iron (µg/dl)	Transferrin saturation (%)	TIBC (µg/dl)	UIBC (µg/dl)	CRP (mg/l)	Dietary iron (mg/day)	Total iron (mg/day)	
Age at blood draw (years)	1									
Ferritin (ng/ml)	-0.13 (0.01)	1								
Iron (µg/dl)	-0.06 (0.28)	0.20 (<0.001)	1							
Transferrin saturation (%)	-0.02 (0.68)	0.17 (0.002)	0.87 (<0.001)	1						
TIBC (µg/dl)	-0.04 (0.44)	0.03 (0.59)	0.30 (<0.001)	-0.15 (0.006)	1					
UIBC (µg/dl)	-0.01 (0.92)	-0.09 (0.09)	-0.29 (<0.001)	-0.67 (<0.001)	0.82 (<0.001)	1				
CRP (mg/l)	0.02 (0.73)	-0.04 (0.52)	-0.19 (<0.001)	-0.15 (0.005)	-0.09 (0.12)	0.03 (0.59)	1			
Dietary iron (mg/day)	-0.10 (0.07)	-0.08 (0.16)	-0.07 (0.19)	-0.04 (0.49)	-0.07 (0.19)	-0.03 (0.59)	-0.09 (0.09)	1		
Total iron (mg/day)	-0.03 (0.60)	-0.06 (0.28)	0.01 (0.81)	0.06 (0.30)	-0.06 (0.31)	-0.07 (0.25)	0.19 (<0.001)	0.25 (<0.001)	1	
Heme iron proxy (g/day)	-0.08 (0.17)	0.01 (0.90)	-0.06 (0.32)	0.01 (0.86)	-0.10 (0.06)	-0.07 (0.20)	-0.01 (0.85)	0.40 (<0.001)	0.05 (0.40)	1

Values in parentheses represent p values

Table 3

Fully adjusted analyses of the association between iron and gastric cancer

Variable	Controls		All Gastric Cancer			Gastric Cardia Cancer			Gastric Noncardia Cancer			
	Cases	OR	95% CI	p value	Cases	OR	95% CI	p value	Cases	OR	95% CI	p value
<b>Ferritin (ng/ml) <sup>1</sup></b>												
< 96	83	111	referent		22		referent		64		referent	
96 – 156	77	72	0.67	0.43 – 1.04	14	0.91	0.35 – 2.35	0.846	36	0.71	0.37 – 1.36	0.300
157 – 240	82	58	0.52	0.33 – 0.82	18	1.02	0.40 – 2.62	0.970	23	0.36	0.18 – 0.71	<b>0.003</b>
241	76	67	0.69	0.44 – 1.09	23	1.13	0.45 – 2.84	0.792	33	0.56	0.30 – 1.07	0.080
<i>global p value</i>	<i>318</i>	<i>308</i>		<b>0.037</b>	<i>77</i>			<i>0.982</i>	<i>156</i>			<b>0.024</b>
<b>Iron (µg/dl) <sup>1</sup></b>												
< 92	81	91	referent		16		referent		58		referent	
92 – 117	78	77	0.89	0.57 – 1.40	22	1.39	0.54 – 3.57	0.494	41	0.62	0.33 – 1.17	0.138
118 – 145	79	69	0.82	0.52 – 1.29	24	2.08	0.79 – 5.50	0.138	23	0.39	0.19 – 0.78	<b>0.008</b>
146	80	71	0.84	0.53 – 1.33	15	1.06	0.38 – 3.01	0.908	34	0.62	0.32 – 1.21	0.161
<i>global p value</i>	<i>318</i>	<i>308</i>		<i>0.829</i>	<i>77</i>			<i>0.435</i>	<i>156</i>			<i>0.060</i>
<b>Transferrin saturation (%) <sup>1</sup></b>												
< 28.65	78	89	referent		15		referent		56		referent	
28.65 – 35.87	79	69	0.80	0.51 – 1.27	18	0.93	0.35 – 2.47	0.877	34	0.60	0.31 – 1.17	0.131
35.88 – 44.09	81	73	0.77	0.49 – 1.22	21	1.65	0.59 – 4.63	0.343	34	0.58	0.30 – 1.14	0.116
44.10	79	77	0.92	0.58 – 1.45	23	2.19	0.79 – 6.05	0.130	32	0.53	0.27 – 1.03	0.060
<i>global p value</i>	<i>317</i>	<i>308</i>		<i>0.655</i>	<i>77</i>			<i>0.237</i>	<i>156</i>			<i>0.212</i>
<b>TIBC (µg/dl) <sup>1</sup></b>												
< 295	77	77	referent		18		referent		44		referent	
295 – 329	79	92	1.16	0.74 – 1.82	31	2.29	0.94 – 5.58	0.069	41	0.91	0.47 – 1.76	0.789
330 – 361	82	69	0.80	0.50 – 1.27	16	1.63	0.59 – 4.49	0.345	28	0.51	0.26 – 1.00	0.051
362	79	70	0.91	0.57 – 1.46	12	0.61	0.22 – 1.65	0.329	43	1.43	0.73 – 2.80	0.297
<i>global p value</i>	<i>317</i>	<i>308</i>		<i>0.420</i>	<i>77</i>			<i>0.038</i>	<i>156</i>			<b>0.033</b>
<b>UIBC (µg/dl) <sup>1</sup></b>												
< 174	79	76	referent		21		referent		37		referent	
174 – 202	80	72	0.94	0.59 – 1.49	20	1.11	0.44 – 2.79	0.832	33	0.88	0.45 – 1.72	0.700

Variable	Controls		All Gastric Cancer				Gastric Cardia Cancer				Gastric Noncardia Cancer						
	Cases	OR	95% CI	p value	Cases	OR	95% CI	p value	Cases	OR	95% CI	p value	Cases	OR	95% CI	p value	
203 – 239	80	1.05	0.66 1.65	0.844	23	1.08	0.43 2.72	0.867	42	1.11	0.57 2.18	0.761	42	1.11	0.57 2.18	0.761	
240	78	1.02	0.64 1.61	0.948	13	0.51	0.19 1.33	0.167	44	1.55	0.80 3.01	0.193	44	1.55	0.80 3.01	0.193	
<i>global p value</i>	317			0.971	77			0.343	156			0.379	156			0.379	
<b>Dietary iron (mg/1000 kcal/day) <sup>2</sup></b>																	
< 1.22	80	95	referent		24		referent		48		referent		48		referent		
1.22 – 1.35	80	74	0.90	0.56 1.44	0.663	18	1.39	0.49 3.94	0.531	36	0.85	0.43 1.70	0.644	36	0.85	0.43 1.70	0.644
1.36 – 1.52	80	75	1.03	0.63 1.68	0.918	14	0.84	0.28 2.49	0.755	45	1.31	0.65 2.66	0.453	45	1.31	0.65 2.66	0.453
1.53	78	64	1.05	0.60 1.85	0.864	21	1.55	0.47 5.13	0.476	27	1.01	0.43 2.36	0.985	27	1.01	0.43 2.36	0.985
<i>global p value</i>	318	308		0.931	77			0.627	156			0.629	156			0.629	
<b>Total iron (mg/1000 kcal/day) <sup>2</sup></b>																	
< 1.25	80	103	referent		23		referent		53		referent		53		referent		
1.25 – 1.39	79	66	0.74	0.46 1.18	0.207	16	0.90	0.30 2.67	0.853	32	0.65	0.33 1.28	0.212	32	0.65	0.33 1.28	0.212
1.40 – 1.57	80	71	0.89	0.55 1.45	0.647	15	0.66	0.22 1.99	0.463	37	0.95	0.47 1.91	0.887	37	0.95	0.47 1.91	0.887
1.58	79	68	0.96	0.57 1.61	0.869	23	0.97	0.33 2.84	0.962	34	1.30	0.59 2.84	0.515	34	1.30	0.59 2.84	0.515
<i>global p value</i>	318	308		0.597	77			0.849	156			0.320	156			0.320	
<b>Heme iron proxy (g/1000 kcal/day) <sup>2</sup></b>																	
< 14.50	79	87	referent		20		referent		42		referent		42		referent		
14.50 – 17.49	80	69	0.72	0.45 1.15	0.167	15	0.46	0.17 1.26	0.131	38	0.78	0.39 1.55	0.480	38	0.78	0.39 1.55	0.480
17.50 – 21.45	80	69	0.68	0.42 1.11	0.123	18	0.57	0.20 1.68	0.312	38	0.75	0.36 1.53	0.423	38	0.75	0.36 1.53	0.423
21.46	79	83	0.88	0.52 1.46	0.614	24	0.83	0.27 2.59	0.747	38	0.59	0.27 1.26	0.173	38	0.59	0.27 1.26	0.173
<i>global p value</i>	318	308		0.338	77			0.393	156			0.599	156			0.599	

<sup>1</sup> Logistic regression models adjusted for age at randomization, date of blood draw, randomization (alpha-tocopherol and beta-carotene), energy intake (kilocalories/day), serum C-reactive Protein (mg/L), fiber intake (g/day), education (categorical), and total vitamin C intake (mg/day).

<sup>2</sup> Logistic regression models adjusted for age at randomization, date of blood draw, randomization (alpha-tocopherol and beta-carotene), fiber intake (g/day), education (categorical), total calcium intake (mg/day), vegetable intake (g/day), energy intake (kilocalories/day), cigarettes per day smoked, and years of cigarette smoking. Abbreviations: CI, confidence interval; OR, odds ratio; TIBC, total iron-binding capacity; UIBC, unsaturated iron-binding capacity.

Table 4

Mean levels of serum biomarkers stratified by *Helicobacter pylori* seropositivity and gastric atrophy in all individuals

Exposure	<i>Helicobacter pylori</i>											
	Seronegative					Seropositive						
	n	Median (IQR)	n	Median (IQR)	T-test p value <sup>1</sup>	Global p value <sup>2</sup>	n	Median (IQR)	No	Yes		
Ferritin (ng/ml)	134	177 (103, 272)	546	135 (78, 220)	<0.001	0.134	454	166 (98, 252)	74	85 (49, 150)	<0.001	<0.001
Iron (µg/dl)	134	119 (98, 148)	545	116 (87, 145)	0.027	0.139	454	119 (90, 146)	74	117 (97, 143)	0.883	0.241
Transferrin saturation (%)	134	36 (29, 46)	544	36 (27, 44)	0.095	0.350	453	37 (28, 45)	74	36 (29, 44)	0.614	0.113
TIBC (µg/dl)	134	331 (299, 364)	544	324 (293, 359)	0.168	0.395	453	326 (296, 359)	74	329 (291, 365)	0.697	0.770
UIBC (µg/dl)	134	203 (170, 238)	544	204 (174, 241)	0.791	0.778	453	204 (173, 238)	74	200 (159, 244)	0.606	0.148
CRP (mg/l)	134	2.1 (0.8, 4.4)	546	2.1 (0.9, 4.3)	0.425	0.563	454	2.0 (0.9, 4.2)	74	2.1 (1.0, 4.5)	0.455	0.147

<sup>1</sup>The t-test is an unadjusted comparison of means and standard errors of the transformed variable using the best transformation for normality (natural log for ferritin and CRP; square-root for iron, transferrin saturation and UIBC; and inverse of the square-root for TIBC).

<sup>2</sup>Global p value is the likelihood ratio test p value from a comparison of a nested model to a main model with the addition of the quantiled categorical exposure. Both the main and nested models were adjusted for age at randomization, date of blood draw, trial intervention (alpha-tocopherol and beta-carotene), energy intake (kilocalories/day), serum C-reactive Protein (mg/L; apart from the model for CRP), fiber intake (g/day), education (categorical), total vitamin C intake (mg/day), and case-type/control (categorical).

Table 5

Studies which have assessed serum iron metrics in relation to gastric cancer

First Author	Year of Publication	Study	Country	Period of Blood Draw	Last year of Follow-up	Number of Cases	Number of Controls	Gastric Cancer Subsite	Serum Ferritin	Serum Iron	Transferrin Saturation	TIBC	UIBC
<b>Cohort</b>													
Knekt, P.	1994	Mobile Health Clinic Study	Finland	1966–72	1984	120 men, 76 women	21,085 men, 17,714 women	GC	↓*	↓*	↓*	↑*	—
Stevens, R.G.	1994 (& 1988; follow-up through 1984)	NHANES I	USA	1971–1974	1988	10 men	2,908 men	GC	↓	↓	↓	↑	—
Herrinton, L.J.	1995	Kaiser Permanente Multiphasic Health Check-up Evaluation Study	USA	1969–71	1990	32 men, 35 women	10,356 men, 28,115 women	GC	↓	↓	↓	↑	—
<b>Nested Case-Control</b>													
Akiba, S.	1991	Hiroshima and Nagasaki Atomic Bomb Survivors	Japan	1970–72	1983	116 men, 92 women	193 men, 157 women	GC	* ↓	↓	—	—	—
Nomura, A.M.	1992 & 1995	Honolulu Heart Program	Hawaii	1967–70	1989	121 men	121 men	GC	↓	↓	—	—	—
Cook, M.B. /	2011	ATBC Cancer Prevention Study	Finland	1985–88	2006	341 men	341 men	GCC	—	—	—	↑*	—
								GNCC	↓*	↓*	↓*	↑*	—

Arrows represent the general direction of associations between serum markers and gastric cancer (↘ indicates an 'n'-shaped relationship and ↗ indicates a 'u'-shaped relationship). An asterix indicates an association which was statistically significant at  $\alpha=0.05$ . Blue represents associations in men, red in women, and a black asterix indicates that the result also pertains to men and women combined. A dash indicates a null finding. A blank cell indicates that a study did not assess that particular serum marker.

/ This manuscript. Abbreviations: GC, gastric cancer; GCC, gastric cardia cancer; GNCC, gastric noncardia cancer.